|
|
275 Armand-Frappier Blvd.
Laval, Quebec H7V 4A7 Canada
phone:(450) 680-4500
fax:(450) 680-4501
|
|
| Symbol |
NRMX |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.neurochem.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Neurochem is focused on the innovation of therapeutics for neurological disorders. |
|
| Management |
| Dr. Francesco Bellini, Chairman, President and Chief Executive Officer; Dr. Andreas Orfanos, Executive Vice President, Strategic Planning and Scientific Affairs; Dr. Philippe Calais, President, Global Business Neurochem Inc., President of the Board of Directors, Neurochem (International), Limited; Dr. Denis Garceau, Senior Vice President, Drug Development; Mr. Mariano Rodriguez, Vice President, Finance, and Chief Financial Officer; Dr. Daniel Delorme, Vice President, Research; Dr. Lise H?bert, Vice President, Corporate Communications; Ms. Christine Lennon, Vice President, Business Development; Dr. Shona McDiarmid, Vice President, Intellectual Property; Ms. Judith Paquin, Vice President, Human Resources; Mr. David Skinner, Vice President, General Counsel and Corporate Secretary |
| |
|
|
|
|
|
|
|
|
|
|
|
| Description |
|
Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The company's staged pipeline of proprietary, disease-modifying, oral products addresses critical unmet medical needs. Fibrillex, designated an orphan drug, is in Phase II/III clinical trial for AA amyloidosis. Alzhemed has completed a Phase II clinical trial for the treatment of Alzheimer's disease. Cerebril is in a Phase II trial for the prevention of hemorrhagic stroke caused by cerebral amyloid angiopathy. Neurochem is also developing a product for the potential treatment of epileptic seizures induced by traumatic brain injury. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
